|
|
Volumn 14, Issue SUPPL. 1, 1998, Pages 137-142
|
|
Is price regulation necessary? A summary of the arguments
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDEPRESSANT AGENT;
ANTIHISTAMINIC AGENT;
ANTIHYPERTENSIVE AGENT;
ANTILIPEMIC AGENT;
ANTIRETROVIRUS AGENT;
ANTIULCER AGENT;
ANTIVIRUS AGENT;
ASTEMIZOLE;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CALCIUM ANTAGONIST;
CAPTOPRIL;
CARDIOVASCULAR AGENT;
CIMETIDINE;
DIDANOSINE;
DILTIAZEM;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ENALAPRIL MALEATE;
FLUOXETINE;
HUMAN GROWTH HORMONE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
METOPROLOL TARTRATE;
MEVINOLIN;
NIFEDIPINE;
PRAVASTATIN;
PROPRANOLOL;
PROTOPINE;
RANITIDINE;
RECOMBINANT HORMONE;
SEROTONIN UPTAKE INHIBITOR;
SERTRALINE;
TERFENADINE;
UNINDEXED DRUG;
ZIDOVUDINE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ALLERGY;
ANGINA PECTORIS;
CONFERENCE PAPER;
COST CONTROL;
DEPRESSION;
DRUG APPROVAL;
DRUG COST;
DRUG INDUSTRY;
DRUG RESEARCH;
GROWTH HORMONE DEFICIENCY;
HEALTH CARE SYSTEM;
HYPERCHOLESTEROLEMIA;
HYPERTENSION;
PRIORITY JOURNAL;
COST CONTROL;
DRUG COSTS;
DRUG INDUSTRY;
|
|
EID: 0031823173
PISSN: 11707690
EISSN: None
Source Type: Journal
DOI: 10.2165/00019053-199814001-00016 Document Type: Conference Paper |
|
Times cited : (6)
|
|
References (1)
|
